Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature
Open Access
- 1 December 2019
- journal article
- review article
- Published by World Scientific Pub Co Pte Ltd in Journal of Porphyrins and Phthalocyanines
- Vol. 23 (11n12) , 1229-1240
Abstract
The therapeutic value of vascular targeted photodynamic therapy (VTP) for cancer has already been recognized in the clinic: TOOKAD®has been clinically approved in Europe and Israel for treatment of men with low-risk prostate cancer. When light is applied shortly after intravenous administration of the photosensitizer, the damage is primarily done to the vasculature. This results in vessel constriction, blood flow stasis, and thrombus formation. Subsequently, the tumor is killed due to oxygen and nutrient deprivation. To further increase treatment specificity and to reduce undesired side effects such as damaging to the surrounding healthy tissues, efforts have been made to selectively target the PS to the tumor vasculature, an approach named molecular targeted VTP (molVTP). Several receptors have already been explored for this approach, namely CD13, CD276, Extra domains of fibronectin (A, B), Integrin [ ]v[ ]3, Neuropilin-1, Nucleolin, PDGFR[ ], tissue factor, and VEGFR-2, which are overexpressed on tumor vasculature. Preclinical studies have shown promising results, further encouraging the investigation and future application of molVTP, to improve selectivity and efficacy of cancer treatment. This strategy will hopefully lead to even more selective treatments for many cancer patients.Keywords
Funding Information
- the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (677582)
This publication has 81 references indexed in Scilit:
- Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the LungPLOS ONE, 2013
- Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancerInternational Journal of Nanomedicine, 2013
- Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin ProdrugMolecular Pharmaceutics, 2011
- A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vesselsBritish Journal of Cancer, 2011
- Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor ModalitiesPharmaceuticals, 2010
- Neuropilin-1 Targeting Photosensitization-Induced Early Stages of Thrombosis via Tissue Factor ReleasePharmaceutical Research, 2010
- Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot studyBMC Cancer, 2010
- Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast CancerThe American Journal of Pathology, 2009
- Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlationsAnnals of Oncology, 2008
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008